Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery.

[1]  A. Schouten,et al.  The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: A meta-analysis , 2009, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[2]  Elizabeth C. Wilson,et al.  The Impact of Aprotinin on Postoperative Renal Dysfunction in Neonates Undergoing Cardiopulmonary Bypass: A Retrospective Analysis , 2009, Anesthesia and analgesia.

[3]  A. Laupacis,et al.  The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis , 2009, Canadian Medical Association Journal.

[4]  R. Lange,et al.  The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  R. Lange,et al.  The Risks of Aprotinin and Tranexamic Acid in Cardiac Surgery: A One-Year Follow-Up of 1188 Consecutive Patients , 2008, Anesthesia and analgesia.

[6]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[7]  M. Eaton.  Antifibrinolytic Therapy in Surgery for Congenital Heart Disease , 2008, Anesthesia and analgesia.

[8]  M. Kertai,et al.  Aprotinin and renal dysfunction after pediatric cardiac surgery , 2007, Paediatric anaesthesia.

[9]  Jeremiah R. Brown,et al.  Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery , 2007, Circulation.

[10]  L S Jefferson,et al.  Modified RIFLE criteria in critically ill children with acute kidney injury. , 2007, Kidney international.

[11]  A. Hoeft,et al.  Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. , 2007, JAMA.

[12]  T. Ferguson.  Aprotinin--are there lessons learned? , 2007, JAMA.

[13]  P. Mannucci,et al.  Drug therapy: Prevention and treatment of major blood loss , 2007 .

[14]  P. Kumar,et al.  Prevention and treatment of major blood loss. , 2007, The New England journal of medicine.

[15]  S. Chauhan,et al.  Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. , 2004, Journal of cardiothoracic and vascular anesthesia.

[16]  W. Sieghart,et al.  Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. , 2002, The Journal of pharmacology and experimental therapeutics.

[17]  Kimberlee Gauvreau,et al.  Consensus-based method for risk adjustment for surgery for congenital heart disease. , 2002, The Journal of thoracic and cardiovascular surgery.

[18]  D. Devine,et al.  Hemostatic Parameters and Platelet Activation Marker Expression in Cyanotic and Acyanotic Pediatric Patients Undergoing Cardiac Surgery in the Presence of Tranexamic Acid , 2000, Thrombosis and Haemostasis.

[19]  P. Lange,et al.  Peritoneal dialysis after infant open heart surgery: observations in 27 patients. , 1999, The Annals of thoracic surgery.

[20]  K. Peltola,et al.  Venous thrombosis in pediatric cardiac surgery. , 1997, Journal of cardiothoracic and vascular anesthesia.

[21]  J. Mathew,et al.  A67 REDUCED BLOOD LOSS AT THE EXPENSE OF RENAL FUNCTION: IS EPSILON-AMINOCAPROIC ACID A BLOW TO THE KIDNEY? , 1997 .

[22]  D. Wensley,et al.  Peritoneal dialysis in children after cardiopulmonary bypass. , 1997, The Journal of thoracic and cardiovascular surgery.

[23]  L. Brion,et al.  The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. , 1987, Pediatric clinics of North America.

[24]  A. Atkinson,et al.  Kinetics of epsilon‐aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects , 1984, Clinical pharmacology and therapeutics.